surpass trial tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 Overview of the SURPASS phase
Pay in 4 interest-free payments of $6.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1










:max_bytes(150000):strip_icc()/26Q1_WL_oral-sema_newsroom_1920x1008-1dfa18327b724266bed50c36ab0b9d49.jpg)















